BioNTech SE

WBAG:BNTX Stock Report

Market Cap: €21.1b

BioNTech Management

Management criteria checks 4/4

BioNTech's CEO is Ugur Sahin, appointed in Jan 2008, has a tenure of 18.67 years. total yearly compensation is €1.06M, comprised of 66.4% salary and 33.6% bonuses, including company stock and options. directly owns 15.89% of the company’s shares, worth €3.34B. The average tenure of the management team and the board of directors is 3 years and 4.3 years respectively.

Key information

Ugur Sahin

Chief executive officer

€1.1m

Total compensation

CEO salary percentage66.35%
CEO tenure18.7yrs
CEO ownership15.9%
Management average tenure3yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ugur Sahin's remuneration changed compared to BioNTech's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-€2b

Mar 31 2026n/an/a

-€1b

Dec 31 2025€1m€700k

-€1b

Sep 30 2025n/an/a

-€572m

Jun 30 2025n/an/a

-€345m

Mar 31 2025n/an/a

-€766m

Dec 31 2024€265m€700k

-€665m

Sep 30 2024n/an/a

-€467m

Jun 30 2024n/an/a

-€504m

Mar 31 2024n/an/a

€113m

Dec 31 2023€1m€700k

€930m

Sep 30 2023n/an/a

€3b

Jun 30 2023n/an/a

€4b

Mar 31 2023n/an/a

€6b

Dec 31 2022€6m€360k

€9b

Sep 30 2022n/an/a

€10b

Jun 30 2022n/an/a

€12b

Mar 31 2022n/an/a

€13b

Dec 31 2021€12m€360k

€10b

Sep 30 2021n/an/a

€7b

Jun 30 2021n/an/a

€4b

Mar 31 2021n/an/a

€1b

Dec 31 2020€17m€360k

€15m

Sep 30 2020n/an/a

-€410m

Jun 30 2020n/an/a

-€230m

Mar 31 2020n/an/a

-€192m

Dec 31 2019€7m€311k

-€179m

Compensation vs Market: Ugur's total compensation ($USD1.22M) is below average for companies of similar size in the Austrian market ($USD4.91M).

Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.

CEO

Ugur Sahin (61 yo)

18.7yrs
Tenure
€1,055,000
Compensation

Prof. Dr. Ugur Sahin, MD, is Member of Management Board of CureVac SE from December 2025. He is Co-Founder & Chief Executive Officer of BioNTech US Inc and also serves as its Member of Management Board fro...

Leadership Team

NamePositionTenureCompensationOwnership
Ugur Sahin
Co-Founder18.7yrs€1.06m15.89%
€ 3.3b
Ozlem Tureci
Co-Founder8.7yrs€841.00k0.049%
€ 10.3m
Ramon Zapata-Gomez
CFO & Member of Management Board1.2yrs€1.02mno data
Sierk Pötting
MD, COO & Member of Management Board12.7yrs€868.00k0.22%
€ 45.5m
James Timothy Ryan
Chief Legal & Business Officer and Member of the Management Board3yrs€981.00k0.0019%
€ 402.2k
Annemarie Hanekamp
Chief Commercial Officer & Member of Management Boardno data€1.17mno data
Kylie Jimenez
Chief People Officer & Member of Management Boardless than a yearno datano data
Lisa Birringer
Senior Vice President of Global Financial Reporting & Accounting1.9yrsno datano data
Douglas Maffei
Vice President of Strategy & Investor Relationsno datano datano data
Jasmina Alatovic
Vice President Corporate Communicationsno datano datano data
Oliver Henning
Senior Vice President of Operationsno datano datano data
Sebastian Kreiter
Senior Vice President of Immunotherapy & Preclinical Researchno datano datano data
3.0yrs
Average Tenure
52yo
Average Age

Experienced Management: BNTX's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rudolf Staudigl
Supervisory Board Member4.3yrs€160.00k0.00016%
€ 33.7k
Ulrich Wandschneider
Independent Deputy Chairman Supervisory Board8.7yrs€220.00k0.00059%
€ 124.2k
Michael Motschmann
Independent Supervisory Board Member18.7yrs€140.00kno data
Susanne Schaffert
Member of Supervisory Boardless than a yearno datano data
Helmut Jeggle
Independent Supervisory Board Chairman18.7yrs€400.00k0.13%
€ 27.9m
Iris Low-Friedrich
Member of Supervisory Boardless than a yearno datano data
Nicola Blackwood
Member of Supervisory Board3.3yrs€140.00kno data
Anja Morawietz
Supervisory Board Member4.3yrs€180.00k0.00010%
€ 21.1k
4.3yrs
Average Tenure
62yo
Average Age

Experienced Board: BNTX's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 20:06
End of Day Share Price 2026/09/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioNTech SE is covered by 31 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harry GillisBerenberg
Zhiqiang ShuBerenberg
Samuel EnglandBerenberg